Toxicology Unit, Department of Clinical Biochemistry, Bessemer Wing, King's College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, United Kingdom.
Forensic Sci Int. 2013 Jun 10;229(1-3):145-50. doi: 10.1016/j.forsciint.2013.02.010. Epub 2013 Mar 9.
Therapeutic drug monitoring (TDM) of atypical antipsychotics is common, but published methods often specify relatively complex sample preparation and analysis procedures. The aim of this work was to develop and validate a simple liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the analysis of amisulpride, aripiprazole and dehydroaripiprazole, clozapine and norclozapine, olanzapine, quetiapine, risperidone and 9-hydroxyrisperidone, and sulpiride in small (200 μL) volumes of plasma or serum for TDM purposes. The applicability of the method as developed to haemolysed whole blood and to oral fluid was also investigated. Analytes and internal standards were extracted into butyl acetate:butanol (9+1, v/v) and a portion of the extract analysed by LC-MS/MS (100 mm × 2.1 mm i.d. Waters Spherisorb S5SCX; eluent: 50 mmol/L methanolic ammonium acetate, pH* 6.0; flow-rate 0.5 mL/min; positive ion APCI-SRM, two transitions per analyte). Assay calibration (human plasma, oral fluid, and haemolysed whole blood calibration solutions) was performed by plotting the ratio of the peak area of the analyte to that of the appropriate internal standard. Assay validation was as per FDA guidelines. Assay calibration was linear across the concentration ranges studied. Inter- and intra-assay precision and accuracy were within 10% for all analytes in human plasma. Similar results were obtained for oral fluid and haemolysed whole blood, except that aripiprazole and dehydroaripiprazole were within 15% accuracy at low concentration (15 μg/L) in oral fluid, and olanzapine inter-assay precision could not be assessed in these matrices due to day-by-day degradation of this analyte. Recoveries varied between 16% (sulpiride) and 107% (clozapine), and were reproducible as well as comparable between human plasma, human serum, calf serum and haemolysed whole blood. For oral fluid, recoveries were reproducible, but differed slightly from those in plasma suggesting the need for calibration solutions to be prepared in this medium if oral fluid is to be analysed. LLOQs were 1-5 μg/L depending on the analyte. Neither ion suppression/enhancement, nor interference from some known metabolites of the antipsychotics studied has been encountered. The method has also been applied to the analysis of blood samples collected post-mortem after dilution (1+1, 1+3; v/v) in analyte-free calf serum.
治疗药物监测(TDM)的非典型抗精神病药物是常见的,但发表的方法通常指定相对复杂的样品制备和分析程序。本工作的目的是开发和验证一种简单的液相色谱-串联质谱(LC-MS/MS)方法,用于分析氨磺必利、阿立哌唑和去氢阿立哌唑、氯氮平与去甲氯氮平、奥氮平、喹硫平、利培酮和 9-羟基利培酮,以及用于 TDM 目的的血浆或血清中小体积(200μL)的舒必利。还研究了该方法在溶血全血和口服液中的适用性。分析物和内标物用乙酸丁酯:正丁醇(9+1,v/v)提取,并用 LC-MS/MS 分析一部分提取物(100mm×2.1mm id. Waters Spherisorb S5SCX;洗脱液:50mmol/L 甲醇乙酸铵,pH*6.0;流速 0.5mL/min;正离子 APCI-SRM,每个分析物两个转换)。通过绘制分析物峰面积与适当内标物峰面积的比值来进行分析物校准(人血浆、口服液和溶血全血校准溶液)。根据 FDA 指南进行分析物验证。分析物校准在研究浓度范围内呈线性。在人血浆中,所有分析物的日内和日间精密度和准确度均在 10%以内。在口服液和溶血全血中也得到了类似的结果,除了在低浓度(15μg/L)时阿立哌唑和去氢阿立哌唑的准确度在 15%以内,以及由于该分析物每天降解,无法评估这些基质中奥氮平的日内精密度。回收率在 16%(舒必利)和 107%(氯氮平)之间变化,在人血浆、人血清、小牛血清和溶血全血之间重现性和可比较性良好。对于口服液,回收率重现性良好,但与血浆略有不同,这表明如果要分析口服液,则需要在该介质中制备校准溶液。LLOQs 取决于分析物,为 1-5μg/L。未遇到离子抑制/增强,也未遇到研究的抗精神病药物的一些已知代谢物的干扰。该方法还应用于在分析物免费小牛血清中以 1+1、1+3(v/v)稀释后收集的死后血液样本的分析。